[Methylarginies-induced endothelial dysfunction in chronic kidney disease]

Area of Science:

• Nephrology
• Cardiology
• Vascular Biology

Background:

• Chronic kidney disease (CKD) is a significant risk factor for cardiovascular disease (CVD).
• Endothelial dysfunction is increasingly recognized as a critical mediator linking CKD and CVD.
• Nitric oxide (NO) produced by endothelial cells is vital for vascular function, but its production is impaired in CKD.

Purpose of the Study:

• To review the role of asymmetric dimethylarginine (ADMA) in endothelial dysfunction associated with CKD.
• To explore the connection between ADMA, reduced NO bioavailability, and the increased cardiovascular risk in CKD patients.
• To highlight ADMA as a potential biomarker for both CKD and CVD.

Main Methods:

• Literature review focusing on studies investigating ADMA, endothelial function, and cardiovascular outcomes in CKD.
• Analysis of mechanisms underlying ADMA accumulation and its inhibitory effects on nitric oxide synthase (NOS).
• Synthesis of clinical data demonstrating elevated ADMA levels in populations with renal and vascular diseases.

Main Results:

• Reduced NO production in CKD is partly attributed to increased levels of endogenous NOS inhibitors, primarily ADMA.
• Elevated plasma ADMA levels result from both increased synthesis and decreased degradation.
• ADMA accumulation contributes to endothelial dysfunction, hypertension, atherosclerosis, and CVD incidence.

Conclusions:

• ADMA plays a key role in mediating endothelial dysfunction in the context of CKD.
• Increased ADMA levels serve as a significant biomarker for heightened cardiovascular risk in CKD patients.
• Targeting ADMA pathways may offer therapeutic strategies for mitigating CVD in CKD.